Percutaneous coronary intervention in patients with acute coronary syndromes and increased platelet count - 08/05/25
, Yong Zeng a, ⁎ on behalf of the
CCC-ACS Investigators
Graphical abstract |
Highlights |
• | Among patients with ACS, those with higher platelet counts were less likely to undergo PCI. |
• | In patients with elevated platelets, PCI reduced the risk of ischaemic events without increasing bleeding. |
• | The benefit of PCI in this patient population is predominantly driven by its capacity to reduce cardiac mortality. |
Abstract |
Background |
In patients with acute coronary syndromes (ACS) requiring percutaneous coronary intervention (PCI), abnormally elevated platelet counts are often associated with an increased risk of stent thrombosis and bleeding.
Aims |
To explore the associations between clinical benefits and PCI in patients with ACS and elevated platelet counts.
Methods |
Between July 2017 and December 2019, 50,009 patients with ACS were enrolled in the Improving Care for Cardiovascular Disease in China–Acute Coronary Syndrome Project. This study included patients with platelet count≥300×109/L. The primary outcome was net adverse clinical events (NACE), including major adverse cardiovascular or cerebrovascular events (MACCE; all-cause death, myocardial infarction, ischaemic stroke and stent thrombosis) and major bleeding during the index hospitalization. The difference in the risk of NACE between PCI and non-PCI groups was analysed using multivariable analysis and inverse probability of treatment weighting.
Results |
Among 4501 patients, PCI rates decreased as platelet count increased, with 3029 patients ultimately undergoing PCI. These patients exhibited a lower rate of NACE (adjusted odds ratio [OR]: 0.53, 95% confidence interval [95% CI]: 0.37–0.77; P=0.001) and a reduced risk of MACCE (OR: 0.44, 95% CI: 0.29–0.67; P<0.001). No significant differences in major bleeding were observed (adjusted OR: 1.40, 95% CI: 0.62–3.16; P=0.417). Inverse probability of treatment weighting confirmed these findings.
Conclusion |
In patients with ACS and increased platelet counts who have more complex thrombohaemorrhagic profiles, PCI can effectively reduce the risk of ischaemic events without increasing the risk of bleeding.
Clinical Trial Registration |
Keywords : Platelet count, Acute coronary syndromes, Percutaneous coronary intervention, In-hospital outcomes
Plan
Vol 118 - N° 5
P. 304-311 - mai 2025 Retour au numéro
Article précédent
- Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation: Rationale for and design of the AQUATIC double-blind randomized trial
- Romain Didier, Gilles Lemesle, Gilles Montalescot, P.H. Gabriel Steg, Eric Vicaut, Dominique Mottier, Christophe Bauters, Philippe Mabo, Tabassome Simon, Claire Bouleti, Stephane Andrieu, Denis Angoulvant, Gerald Vanzetto, Mathieu Kerneis, Guillaume Cayla, Martine Gilard
- Prognosis of patients with acute myocardial infarction in the setting of COVID-19: A French nationwide observational study
- Ahmad Abou Hamed, Maeva Gourraud, Thibaud Genet, François Barbier, Denis Angoulvant, Laurent Fauchier, Fabrice Ivanes
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?